14:57 EDT Madrigal Pharmaceuticals (MDGL) off highs, remains up 13% in afternoon trading
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal’s Rezdiffra Drives Blockbuster‑Level First Year
- Madrigal Pharmaceuticals price target lowered to $529 from $570 at BofA
- Madrigal Pharmaceuticals: Rezdiffra’s Strong Launch, Expanding Prescriber Adoption, and Advancing Pipeline Underpin Buy Rating
- Madrigal Pharmaceuticals reports Q4 EPS ($2.57), consensus (88c)
- Paulson buys Solstice, exits Honeywell in Q4